Therapeutics MD (TXMD) up 32.5% today; Gets 600% return target from FBR

Biotech stock Therapeutics MD (TXMD) was up 32.5% today. Friedman Billings Ramsey raised their price target for the stock to an incredible $34.

TXMD now trades at $5.47 — the FBR price target would mean a 600% return.

TXMD is owned by the billion dollar biotech hedge fund RA Capital Management. RA is the best in the business of biotech investing, and owns more than 6% of TXMD.

RA is one of our favorite hedge funds to piggyback. Its a billion dollar biotech focused hedge fund run by Peter Kolchinsky, a PHD from Harvard. The fund has one of the best track records in the world, averaging 41% a year since 2002.

Our subscribers are currently up more than 160% on a biotech stock that we followed RA Capital Management into.

Learn more about RA Capital, their portfolio and our Billionaires Portfolio, where we piggyback the best ideas from the biggest, most influential investors.